The Medicines and Healthcare products Regulatory Agency (MHRA) has approved, Thursday, a four-dose version of the diabetes and weight management medicine Mounjaro (tirzepatide).
Eli Lilly And Co’s LLY Mounjaro will be branded as Mounjaro KwikPen in the U.K.
In September, the U.K.’s National Institute for Health and Care Excellence (NICE) endorsed Mounjaro, indicating it as a viable option for patients grappling with poorly controlled type 2 diabetes.
The development occurred against the backdrop of national shortages of Novo Nordisk A/S’s NVO Ozempic, a medication within the same drug class as Mounjaro and approved in the UK for type 2 diabetes.
Mounjaro KwikPen is approved to treat adults with type 2 diabetes and for weight management in adult patients with a BMI of 30kg/m² or more (obesity), as well as those with a BMI between 27-30kg/m² (overweight) who also have weight-related health problems such as prediabetes, high blood pressure, high cholesterol, or heart problems.
The medicine will be used with a reduced-calorie diet and increased physical activity.
Mounjaro KwikPen is available as a four-dose pre-filled injection pen containing 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg of tirzepatide per dose, injected under the skin of a patient’s stomach area, thigh or upper arm.
The starting dose is 2.5mg once a week for four weeks, increasing to 5mg once a week. The dose may then be increased in at least 4-week intervals up to the maximum dose of 15mg once weekly if recommended by the patient’s doctor.
Last week, Eli Lilly unveiled plans to introduce its weight-loss drug Mounjaro in new countries this year while simultaneously expanding manufacturing capacity.
Read Next: Weight-Loss Drug Boom: Philanthropy Powerhouse Emerges As Lilly Endowment Comes Closer To Gates Foundation.
Price Action: LLY shares closed down by 0.95% at $627.67 on Thursday.
Photo via Company
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
